OBI Pharma, Inc. (4174.TWO)
TWD 37.6
(-5.41%)
TWD 37.6
(-5.41%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.08 Billion TWD | -9.24% |
| 2022 | -1.91 Billion TWD | -10.05% |
| 2021 | -1.73 Billion TWD | -16.71% |
| 2020 | -1.48 Billion TWD | -3.26% |
| 2019 | -1.44 Billion TWD | -1.04% |
| 2018 | -1.42 Billion TWD | -20.01% |
| 2017 | -1.18 Billion TWD | -6.94% |
| 2016 | -1.11 Billion TWD | -4.63% |
| 2015 | -1.06 Billion TWD | -49.26% |
| 2014 | -712.32 Million TWD | -52.32% |
| 2013 | -467.65 Million TWD | -64.61% |
| 2012 | -284.1 Million TWD | -100.58% |
| 2011 | -141.63 Million TWD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -545.18 Million TWD | 4.45% |
| 2024 Q1 | -570.55 Million TWD | -17.22% |
| 2024 Q3 | -534.05 Million TWD | 2.04% |
| 2023 Q3 | -623.5 Million TWD | -284.5% |
| 2023 Q4 | -486.74 Million TWD | 21.93% |
| 2023 FY | -2.08 Billion TWD | -9.24% |
| 2023 Q1 | -421.58 Million TWD | 37.4% |
| 2023 Q2 | 337.94 Million TWD | 180.16% |
| 2022 FY | -1.91 Billion TWD | -10.05% |
| 2022 Q3 | -453.08 Million TWD | -10.05% |
| 2022 Q1 | -374.88 Million TWD | 32.87% |
| 2022 Q2 | -411.69 Million TWD | -9.82% |
| 2022 Q4 | -673.43 Million TWD | -48.63% |
| 2021 Q4 | -558.41 Million TWD | -41.06% |
| 2021 FY | -1.73 Billion TWD | -16.71% |
| 2021 Q2 | -432.04 Million TWD | -52.73% |
| 2021 Q3 | -395.87 Million TWD | 8.37% |
| 2021 Q1 | -282.89 Million TWD | 37.27% |
| 2020 Q1 | -369.49 Million TWD | 15.91% |
| 2020 Q3 | -365.55 Million TWD | -30.62% |
| 2020 Q2 | -279.85 Million TWD | 24.26% |
| 2020 FY | -1.48 Billion TWD | -3.26% |
| 2020 Q4 | -450.98 Million TWD | -23.37% |
| 2019 Q2 | -413.82 Million TWD | -58.93% |
| 2019 FY | -1.44 Billion TWD | -1.04% |
| 2019 Q1 | -260.38 Million TWD | 42.24% |
| 2019 Q3 | -337.23 Million TWD | 18.51% |
| 2019 Q4 | -439.42 Million TWD | -30.3% |
| 2018 Q3 | -440.09 Million TWD | -37.15% |
| 2018 Q1 | -215.88 Million TWD | 32.83% |
| 2018 FY | -1.42 Billion TWD | -20.01% |
| 2018 Q4 | -450.82 Million TWD | -2.44% |
| 2018 Q2 | -320.88 Million TWD | -48.63% |
| 2017 FY | -1.18 Billion TWD | -6.94% |
| 2017 Q4 | -321.4 Million TWD | 7.17% |
| 2017 Q3 | -346.21 Million TWD | -9.95% |
| 2017 Q2 | -314.86 Million TWD | -52.0% |
| 2017 Q1 | -207.15 Million TWD | 43.3% |
| 2016 FY | -1.11 Billion TWD | -4.63% |
| 2016 Q1 | -281.52 Million TWD | -2.85% |
| 2016 Q4 | -365.38 Million TWD | -17.45% |
| 2016 Q2 | -154.46 Million TWD | 45.13% |
| 2016 Q3 | -311.09 Million TWD | -101.4% |
| 2015 Q2 | -184.03 Million TWD | 50.94% |
| 2015 FY | -1.06 Billion TWD | -49.26% |
| 2015 Q4 | -273.72 Million TWD | -18.83% |
| 2015 Q3 | -230.34 Million TWD | -25.16% |
| 2015 Q1 | -375.1 Million TWD | -88.18% |
| 2014 Q3 | -160.28 Million TWD | 29.75% |
| 2014 Q2 | -228.15 Million TWD | -83.19% |
| 2014 Q1 | -124.54 Million TWD | 12.64% |
| 2014 FY | -712.32 Million TWD | -52.32% |
| 2014 Q4 | -199.33 Million TWD | -24.37% |
| 2013 Q1 | -110.58 Million TWD | -31.48% |
| 2013 Q2 | -166.07 Million TWD | -50.19% |
| 2013 FY | -467.65 Million TWD | -64.61% |
| 2013 Q3 | -103.92 Million TWD | 37.42% |
| 2013 Q4 | -142.56 Million TWD | -37.17% |
| 2012 Q4 | -84.1 Million TWD | 0.0% |
| 2012 Q3 | -84.1 Million TWD | 0.0% |
| 2012 FY | -284.1 Million TWD | -100.58% |
| 2011 FY | -141.63 Million TWD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Great Novel Therapeutics Biotech & Medicals | -65.81 Million TWD | -3075.009% |
| Gwo Xi Stem Cell Applied Technology Co. , Ltd | -93.95 Million TWD | -2124.247% |
| Visgeneer Inc. | -21.15 Million TWD | -9776.606% |
| Genomics BioSci & Tech. Co.,Ltd. | -84.99 Million TWD | -2358.751% |
| Advagene Biopharma Co., Ltd. | -93.33 Million TWD | -2138.998% |
| Sagittarius Life Science Corp | -64.37 Million TWD | -3146.227% |
| NaviFUS Corp. | -76.42 Million TWD | -2634.398% |
| BioGend Therapeutics Co., Ltd. | -176.54 Million TWD | -1083.743% |
| Shine-On BioMedical Co.,Ltd. | -62.68 Million TWD | -3233.904% |
| TaiRx, Inc. | -214.69 Million TWD | -873.377% |
| Andros Pharmaceuticals Co.,Ltd | -67.69 Million TWD | -2986.977% |
| Lin BioScience, Inc. | -1.09 Billion TWD | -90.531% |
| TaiwanJ Pharmaceuticals Co., Ltd. | -6.61 Million TWD | -31515.598% |
| Lumosa Therapeutics Co., Ltd. | -375.62 Million TWD | -456.35% |
| Anti-Microbial Savior BioteQ Co., Ltd | -56.74 Million TWD | -3582.516% |
| BioLASCO Taiwan Co., Ltd. | 63.33 Million TWD | 3399.583% |
| SYN-TECH Chem. & Pharm. Co., Ltd. | 281.85 Million TWD | 841.452% |
| Sunmax Biotechnology Co., Ltd. | 894.79 Million TWD | 333.55% |
| RBC Bioscience Corporation | 14.53 Million TWD | 14473.691% |
| Bio Preventive Medicine Corp. | -70.58 Million TWD | -2860.799% |
| Syngen Biotech Co.,Ltd. | 334.08 Million TWD | 725.532% |
| G&E Herbal Biotechnology Co., Ltd. | 80.68 Million TWD | 2690.093% |
| AP Biosciences Inc | -347.47 Million TWD | -501.417% |
| EirGenix Inc. | -1.03 Billion TWD | -102.504% |
| Enimmune corporation | -243.47 Million TWD | -758.319% |
| Lukas Biomedical Inc. | -43.56 Million TWD | -4697.5% |
| GlycoNex Incorporation | -259.86 Million TWD | -704.186% |
| BRIM Biotechnology, Inc. | -694.12 Million TWD | -201.068% |
| Level Biotechnology Inc. | 67.55 Million TWD | 3193.603% |
| Pharmosa Biopharm Inc. | -2.82 Million TWD | -73901.098% |
| TaiMed Biologics Inc. | -166.23 Million TWD | -1157.161% |
| Mycenax Biotech Inc. | -602.1 Million TWD | -247.083% |
| SynCore Biotechnology Co.,Ltd | -45.5 Million TWD | -4492.745% |
| Eusol Biotech Co.,Ltd. | -41.48 Million TWD | -4937.826% |
| Taiwan Advance Bio-Pharmaceutical Inc. | -2.25 Million TWD | -92655.925% |
| Feng Chi Biotech Corp. | 24.16 Million TWD | 8749.081% |
| NeoCore Technology Co., Ltd. | -84.94 Million TWD | -2360.198% |
| TWi Biotechnology, Inc. | -169.55 Million TWD | -1132.508% |
| Neith Corporation | -48.85 Million TWD | -4177.625% |
| Sunny Pharmtech Inc. | -72.09 Million TWD | -2798.623% |
| VBI | -16.13 Million TWD | -12854.321% |
| BiOptic Inc. | 44.05 Million TWD | 4843.811% |
| Ever Supreme Bio Technology Co., Ltd | 337.73 Million TWD | 718.772% |
| Sinew Pharma Inc. | -186.25 Million TWD | -1022.017% |
| Greenyn Biotechnology Co., Ltd | 159.81 Million TWD | 1407.615% |
| GeneReach Biotechnology Corp. | -229.28 Million TWD | -811.438% |
| CHO Pharma, Inc. | -268.99 Million TWD | -676.88% |
| Medigen Biotechnology Corp. | -1.23 Billion TWD | -69.476% |
| 3D Global Biotech Inc. | -62.85 Million TWD | -3224.887% |
| Senhwa Biosciences, Inc. | -311.11 Million TWD | -571.719% |
| Intech Biopharm Corporation | -304.39 Million TWD | -586.537% |
| Oneness Biotech Co., Ltd. | -1.09 Billion TWD | -90.566% |
| TCI GENE Inc. | 10.04 Million TWD | 20896.01% |
| MegaPro Biomedical Co., Ltd | -127.25 Million TWD | -1542.182% |
| Taiwan Bio Therapeutics Co., Ltd | -212.2 Million TWD | -884.803% |
| NatureWise Biotech & Medicals Corporation | 3.43 Million TWD | 60955.882% |
| PharmaEngine, Inc. | 277.18 Million TWD | 853.939% |
| Savior Lifetec Corporation | -2.42 Million TWD | -86255.0% |
| TaiGen Biopharmaceuticals Holdings Limited | -174.69 Million TWD | -1096.224% |
| Meribank Biotech Co., Ltd | -123.15 Million TWD | -1596.893% |
| Medigen Vaccine Biologics Corporation | -1.21 Billion TWD | -72.165% |
| Acepodia, Inc. | -435.97 Million TWD | -379.338% |
| Caliway Biopharmaceuticals Co., Ltd. | -487.95 Million TWD | -328.274% |